June 24, 2019
VALBIOTIS Participates in France Biotech’s first HealthTech Investor Days
Valbiotis will participate in the first HealthTech Investor Days, being held June 24-25 in Paris.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
June 23, 2019
Dr. Reddy’s Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
June 21, 2019
Piramal Pharma Solutions invests $10 M to expand its high potency API capability
Piramal Pharma Solutions (PPS), has invested $10 million for a new wing at the Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs).
June 21, 2019
Sanofi, Regeneron’s monotherapy reduces loss of asthma control, improves lung function vs placebo
Sanofi and Regeneron Pharmaceuticals said Friday a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.
June 20, 2019
Syntrix doses first metastatic melanoma patient testing dual inhibotor of CXCR1/2 with Merck’s Keytruda
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.
June 20, 2019
Edesa Biotech continues testing potential dermatitis treatment EB01
Edesa Biotech may continue with its clinical investigation of potential treatment for chronic allergic contact dermatitis EB01, a novel sPLA2 inhibitor, after FDA’s approval.
June 20, 2019
Camurs gets FDA’s green light to kick off phase 3 testing of treatment of acromegaly and neuroendocrine tumors
Camurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.
June 20, 2019
Horizon Therapeutics evaluates Krystexxa in combination with methotrexate to increase response rates and duration of therapy
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
June 20, 2019
CORRECTING and REPLACING Kowa Pharmaceuticals America, Inc. Receives Pediatric Indication and Six-Month Pediatric Exclusivity for LIVALO® (pitavastatin)
MONTGOMERY, Ala.–(BUSINESS WIRE)–Remove the three paragraphs with headings INDICATIONS AND USAGE, PRIMARY HYPERLIPIDEMIA AND MIXED DYSLIPIDEMIA, and LIMITATIONS OF USE…
June 20, 2019
Axial Biotherapeutics bags $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis
$10M investment as Series B extension, bringing total amount raised to $35M –
– Direct investment for the discovery of gut targeted, small molecule therapeutics in oncology utilizing Axial’s novel platform technology